1801 Augustine Cut-Off
About Incyte Corporation
Drug Discovery & Development
Since we began our drug-discovery and development activities in early 2002, we have filed Investigational New Drug (IND) applications and progressed multiple internally developed proprietary compounds into clinical development. In late 2011, we received our first US Food and Drug Administration approval for Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor.
Incyte has an exceptional team of drug discovery and development scientists led by distinguished executives with proven records of success and many scientific and clinical achievements. We employ only the best and those who adhere to the highest standards of scientific and clinical rigor, and we resource our programs for success. We have a strong discovery team that is tightly integrated with all disciplines, including development, regulatory, and commercial operations. Our therapeutic focus is primarily on oncology.
One Molecule at a Time
421 articles with Incyte Corporation
Incyte Corporation announced today that it has scheduled its third quarter 2018 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 30, 2018.
Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
Study met primary and key secondary endpoints, demonstrating significant improvement from baseline in EASI score and reduced itch compared to vehicle
In Honor of MPN Awareness Day and Blood Cancer Awareness Month, Incyte Debuts Documentary Spotlighting Myeloproliferative Neoplasms (MPNs)
Directed by an Academy Award® winning filmmaker in the documentary short subject category, “Something So Rare” chronicles the lives of four people living with MPNs, rare blood cancers
This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or ...
Total product-related revenues of $421 million in Q2 2018, representing 29 percent growth over the same period last year
Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)
Eli Lilly and Company and Incyte Corporation announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 study for baricitinib were published by The Lancet.
Incyte Corporation announced that it has scheduled its second quarter 2018 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 31, 2018.
Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi®) in Steroid-Refractory Acute Graft-Versus-Host Disease
Results support planned sNDA submission in 2018
Shares of Incyte Corporation are up slightly this morning after the company started off its annual R&D day with positive news from its pivotal REACH1 study of Jakafi (ruxolitinib) in steroid-refractory acute graft-versus-host disease (GVHD) and sets up the filing of a supplemental New Drug Applic...
FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved the 2-mg dose of OLUMIANT® (baricitinib), a once-daily oral medication for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA).
Incyte Corporation reports 2018 first-quarter financial results, highlighting strong growth in total product-related revenue and providing a status update on the Company’s development portfolio.
4/25/2018Sometimes it feels like biotech’s successes and failures come in waves—even when it involves entirely unrelated clinical programs. This past month has had many in industry feeling like they’re underwater.
Ahead of next Monday’s U.S. Food and Drug Administration (FDA) committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis, concerns over blood clots, may scuttle the drug’s chances.
Incyte Corporation announced that it has scheduled its first quarter 2018 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 1, 2018.
Roche announced it had temporarily halted recruiting patients to its Phase II MODUL clinical trial for metastatic colorectal cancer after four patient deaths. The patients were receiving Tecentriq (atezolizumab) in combination with Exelixis’ MEK inhibitor Cotellic (cobimetinib).
Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma
The study did not meet the primary endpoint of improving progression-free survival in the overall population compared to KEYTRUDA monotherapy
Shares of Incyte Corporation are down more than 20 percent this morning after the company revealed that pairing is IDO1 drug in combination with Merck’s Keytruda failed to meet endpoints in a Phase III melanoma trial.
Versant Ventures spinoff company Tempest Therapeutics secured $70 million in a Series B funding to advance the company’s immunotherapy pipeline.
On April 23, the FDA’s arthritis advisory committee will take another look at Eli Lilly's re-submission for their moderate-to-severe rheumatoid arthritis drug.
Incyte Targeted Therapy and Immuno-Oncology Portfolio to be Featured in 15 Abstracts at the AACR Annual Meeting 2018
Incyte Corporation (Nasdaq:INCY) announces that 15 abstracts from its research and development portfolio will be presented at the upcoming 2018 American Association for Cancer Research (AACR) annual meeting in Chicago, Illinois from April 14-18, 2018.